Alaunos now describes itself as a developer of oral therapeutics targeting obesity as a potential alternative to injectable GLP-1 drugs. Its lead candidate, ALN1003, has generated positive preclinical proof-of-concept data, with the company reporting metabolic improvements, including weight loss and improved insulin sensitivity, in …
SOHM develops, manufactures, markets and distributes generic and private-label pharmaceutical products in the United States, spanning analgesics, antibiotics, anti-cold and anti-inflammatory medicines, along with cosmeceutical and nutraceutical lines. More recently, the company has promoted a gene-editing effort branded ABBIE and a collaboration with Coastar …
Ultragenyx develops treatments for rare and ultra-rare genetic diseases, spanning approved products such as Crysvita, Dojolvi and Mepsevii alongside a deep gene-therapy and RNA pipeline. In August 2026, the company disclosed U.S. FDA approval of GENGLYCOS, its gene therapy for Glycogen Storage Disease Type …
Agios is built around PYRUKYND (mitapivat), an oral pyruvate kinase activator, following the company's earlier exit from oncology. Its most consequential near-term event is regulatory: the FDA granted priority review to a supplemental application for mitapivat in sickle cell disease, with a decision date …
Axim develops diagnostic healthcare solutions for ophthalmological conditions, including point-of-care tests for dry eye disease and allergic conjunctivitis, and it has operated a center for custom biomarker and biopharmaceutical research. The most consequential recent corporate event, however, is regulatory housekeeping rather than product news: …
Based in Tel Aviv, Enlivex develops Allocetra, an allogeneic, off-the-shelf cell-based immunotherapy designed to rebalance the immune system. Its lead indication is age-related symptomatic primary knee osteoarthritis in older patients. In July 2026 the company said Allocetra received U.S. Food and Drug Administration Regenerative …
Based in Phoenix, Arizona, Creative Medical Technology develops cell-based and immunotherapy products across regenerative medicine, immunology and urology. Its lead clinical asset is CELZ-201, also known as olastrocel, an allogeneic cell therapy being studied for chronic lower back pain caused by degenerative disc disease. …
SQZ Biotechnologies was a Massachusetts-based, clinical-stage company developing cell-engineering therapies using its proprietary "Cell Squeeze" platform, which momentarily deforms a cell's membrane to deliver antigens and other cargo, with lead programs in immuno-oncology. The company's most consequential recent development is procedural: SEC records show …
GelStat Corporation, incorporated in Delaware and based in Miami, is classified under pharmaceutical preparations and traces its corporate history back to an entity formerly named Developed Technology Resource Inc before adopting the GelStat name in 2003. Rather than filing standard 10-Ks and 10-Qs, GelStat …
Revelation Biosciences is developing Gemini, a phosphorylated hexaacyl disaccharide (PHAD)-based immunomodulator, with its lead program targeting acute kidney injury (AKI), a common and serious complication with few effective preventive therapies. The most recent verified milestone came on August 19, 2026, when Revelation said it …